Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland. (4th May 2022)

• Record Type: Journal Article
• Authors: Deb, Arijita; Guggisberg, Patrik; Mutschler, Thomas; Owusu-Edusei, Kwame; Bencina, Goran; Johnson, Kelly D.; Ignacio, Tim; Mathijssen, Daan A.R.; Qendri, Venetia
• Is Part Of: Expert review of vaccines. Volume 21:Number 5(2022)
• Page Start: 711
• Page End: 722
• Publication Date: 2022-05-04
• Subjects: Pneumococcal disease -- pneumococcal vaccination -- Switzerland -- non-bacteremic pneumococcal pneumonia -- conjugate vaccine -- high-risk adults; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1080/14760584.2022.2046468
• Languages: English
• ISSNs: 1476-0584

Abstract

ABSTRACT: Background: Vaccination against pneumococcal disease (PD) has shown a favorable cost-effectivenessprofile for many national immunization programs. While vaccination efforts have concentrated on children, many adults with underlying illnesses face elevated risks of PD and death. A 15-valent pneumococcal conjugate vaccine (V114) is currently available offering protection against 15 different serotypes and can be used in adults. Research design and methods: We examined the cost-effectiveness of V114 vaccination in high-risk adults, aged 18+, in Switzerland. To this end, a Markov model was constructed estimating the lifetime direct medical costs and clinical effectiveness of V114 vaccination on invasive pneumococcal disease (IPD) and non-bacteremic pneumococcal pneumonia (NBPP). Results: Considering 60% vaccine uptake and direct effects of vaccination, in total 760 IPD and 4, 396 NBPP in- and outpatient cases could be prevented. Vaccinating high-risk adults with V114 led to CHF 37.4 million additional vaccination costs but saved CHF 14.4 million of medical treatment costs. V114 vaccination produced a gain of 2, 095 QALYs and 6, 320 LYs compared with no vaccination, leading to incremental cost-effectiveness ratios of CHF 17, 866/QALY and CHF 15, 616/QALY gained from a health care payer and societal perspective, respectively. Conclusions: This evidence justifies the implementation of V114 vaccination among high-risk adults in Switzerland.